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Abstract
Background: Much attention has been recently focused on the role of cancer stem cells (CSCs) in the initiation
and progression of solid malignancies. Since CSCs are able to proliferate and self-renew extensively due to their
ability to express anti-apoptotic and drug resistant proteins, thus sustaining tumor growth. Therefore, the strategy
to eradicate CSCs might have significant clinical implications. The objectives of this study were to examine the
molecular mechanisms by which epigallocathechin gallate (EGCG) inhibits stem cell characteristics of prostate CSCs,
and synergizes with quercetin, a major polyphenol and flavonoid commonly detected in many fruits and
vegetables.
Results: Our data indicate that human prostate cancer cell lines contain a small population of CD44+CD133+
cancer stem cells and their self-renewal capacity is inhibited by EGCG. Furthermore, EGCG inhibits the self-renewal
capacity of CD44+a2b1+CD133+ CSCs isolated from human primary prostate tumors, as measured by spheroid
formation in suspension. EGCG induces apoptosis by activating capase-3/7 and inhibiting the expression of Bcl-2,
survivin and XIAP in CSCs. Furthermore, EGCG inhibits epithelial-mesenchymal transition by inhibiting the
expression of vimentin, slug, snail and nuclear b-catenin, and the activity of LEF-1/TCF responsive reporter, and also
retards CSC’s migration and invasion, suggesting the blockade of signaling involved in early metastasis.
Interestingly, quercetin synergizes with EGCG in inhibiting the self-renewal properties of prostate CSCs, inducing
apoptosis, and blocking CSC’s migration and invasion. These data suggest that EGCG either alone or in
combination with quercetin can eliminate cancer stem cell-characteristics.
Conclusion: Since carcinogenesis is a complex process, combination of bioactive dietary agents with
complementary activities will be beneficial for prostate cancer prevention and/ortreatment.
Background
Prostate cancer currently accounts for 29 percent of all
new cancer diagnoses in men. It is estimated that more
than 27,000 U.S. men died of this disease in 2009, and
this incidence is likely to increase as the male popula-
tion ages [1,2]. The development and progression of
prostate cancer is a slow and complex process that
involves multiple steps of tumorigenic transformation
differentially modulated by endocrine, nutritional and
perhaps inflammatory/immune factors. To date, the
molecular mechanisms that mediate the initiation and
progression of prostate cancer remain poorly under-
stood. Preventive strategies for prostate cancer require
considerable new knowledge about the mechanisms
underlying the pathogenesis and progression of the dis-
ease. Cancer stem cells (CSCs) are generally thought of
as self-renewing cells that are able to reinitiate a tumor
for several generations and can give rise to a spectrum
of differentiated cells [3-5]. CSCs, like normal stem
cells, are also more likely to express antiapoptotic and
drug-resistance genes, making them impervious to most
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anticancer therapeutics [6-13]. In order to eradicate a
tumor and prevent recurrence, it is imperative that can-
cer stem cells be specifically targeted.
Cancer stem/progenitor cells may exhibit characteris-
tics similar to normal stem cells. CSCs have limitless
potential for self-renewal and can efficiently form
tumors in immunodeficient mice that recapitulate the
heterogeneity observed in original tumors [14-17].
Recently, CSCs have been described in several human
tumors including breast, gastrointestinal, lung, prostate,
brain, and melanoma on the basis of their clonogenic
efficiency in vitro and ultimately tumorigenicity in vivo
[15,16,18-21]. The identification and characterization of
CSCs might have enormous clinical implications: for
instance, it is has been shown that CSCs might survive
chemo- as well as radiotherapy [12,22-31], due to the
preferential expression of resistance molecules or activa-
tion of specific signaling pathways. Therefore, under-
standing the mechanisms of drug resistance and
development of novel strategies to kill CSCs are urgently
needed.
Human prostate epithelial (HPE) exhibit stem cell
characteristics, expressing embryonic stem cell markers,
including Oct-4, Nanog, and Sox-2, in addition to the
early progenitor cell markers CD133, CD44, and nestin.
HPET cells do not express p63 and AR, similar to other
reports on prostate stem cells [32,33]. Most importantly,
clonally derived HPET cells are capable of reconstituting
the original prostate tumor from which they were
derived and retain the ability to differentiate into basal,
luminal, and neuroendocrine epithelial cell types of the
prostate in vivo. CD44 is a basal cell marker that has
been studied as a marker for human prostate CSCs
[34,35].
Examination of human prostate cancer cell lines and
xenografts indicate that the CD44+ population is more
proliferative, clonogenic, tumorigenic, and metastatic
than CD44- cells. Prostate cancer cell lines sorted for
high expression of CD44 have been associated with
enhanced expression of “stemness” markers including
BMI, b-catenin, SMO, and Oct 3/4 [36-38]. Moreover,
CD44+a2b1+CD133+ subpopulations obtained from
human tissue have enhanced capacity for in vitro serial
passaging.
Epithelial-mesenchymal transition (EMT) induction in
cancer cells results in the acquisition of invasive and
metastatic properties [13,29,39-41]. Recent reports indi-
cate that the emergence of CSCs occurs in part as a
result of EMT, for example, through cues from tumor
stromal components. CSCs and EMT-type cells, which
shares molecular characteristics with CSCs, have been
believed to play critical roles in drug resistance and
early cancer metastasis as demonstrated in several
human malignancies including prostate cancer
[13,29,39-41]. Thus, the discovery of molecular knowl-
edge of drug resistance and metastasis in relation to
CSCs and EMT in prostate cancer is becoming an
important area of research, and such knowledge is likely
to be helpful in the discovery of newer drugs as well as
designing novel therapeutic strategies for the treatment
of prostate cancer with better outcome.
Epidemiological and dietary intervention studies in
animals and humans have suggested that diet-derived
phenolics, in particular the flavonoids, may play a bene-
ficial role in inhibiting, reversing or retarding tumori-
genesis in many types of cancers, including prostate
cancer [42-47]. Flavonoids are known to possess anti-
inflammatory, anti-oxidant, anti-allergic, hepato-protec-
tive, anti-thrombotic, anti-viral and anti-carcinogenic
activities [42-47]. These activities of flavonoids are
thought to be mediated by interfering with a large num-
ber of mammalian enzymes, such as detoxifying
enzymes that are involved in cell division and prolifera-
tion pathways [42,45,48-50]. Among the flavonoids,
quercetin (3,3’,4’,5,7-pentahydroxyflavone) is a naturally
occurring flavones, and is a component of most edible
fruits and vegetables, with the highest concentrations
being found in onions, apples, and red wine [42,45,51].
Several studies have shown that quercetin has a broad
range of pharmacological properties that include anti-
oxidant and anti-inflammatory activities [52]. Quercetin
treatment has been associated with selective antiproli-
ferative effects and induction of cell death, predomi-
nantly through an apoptotic mechanism, in cancer cell
lines but not in normal cells [53-56]. The anti-prolifera-
tive effect of quercetin is believed to be exerted by pro-
ducing arrest in the G1 phase of the cell cycle or
through interaction with cell cycle-regulated proteins,
like cyclin D1 and CDK4 [57-59]. Quercetin also has
been shown to induce apoptosis by releasing cyto-
chrome c and activating caspase-9 and caspase-3
[60-62]. Moreover, quercetin is believed to be a poten-
tial PI3K inhibitor, an enzyme involved in the pivotal
cell survival pathway [63,64]. Interestingly, quercetin has
been shown to enhance the anticancer activities of sev-
eral chemotherapeutic drugs and inhibit the expression
of P-glycoprotein [65-70]. Therefore, the ability of quer-
cetin to prevent and/or to retard tumor growth is prob-
ably a multifunctional effect. Although the underlying
mechanisms governing these effects are not yet fully
understood, the available evidence collectively indicates
that quercetin may be of therapeutic benefit in clinical
settings, suggesting its potential use as an anticancer
agent or an adjunct to current cancer therapies.
Epigallocathechin gallate (EGCG) from tea has gained
recognition as important chemopreventive agent and as
modulators of tumor cell response to chemotherapy
[71-75]. EGCG downregulates Pg-P and BCRP in a
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tamoxifen resistant MCF-7 cell line [76]. In vitro and
in vivo studies have demonstrated that EGCG affect a
wide array of molecular pathways, resulting in inhibition
of cell growth, invasion, angiogenesis, and metastasis
[77,78]. In prostate cancer, EGCG alter numerous intra-
cellular pathways, including inhibition of ERK1/2- and
Akt-mediated signaling, inhibition of PMA-dependent
PKC activation, alteration of Bcl-2 family members
ratio, and activation of caspases [79-83]. We have
recently demonstrated that EGCG caused growth arrest
at G1 stage of cell cycle through regulation of cyclin D1,
cdk4, cdk6, p21/WAF1/CIP1 and p27/KIP1, and
induced apoptosis through generation of reactive oxygen
species and activation of caspase-3 and caspase-9
[77,78,84]. EGCG inhibited expressions of Bcl-2 and
Bcl-XL and induced expressions of Bax, Bak, Bcl-XS and
PUMA [77,78,84]. Furthermore, the activities of Ras,
Raf-1 and ERK1/2 were inhibited, whereas the activities
of MEKK1, JNK1/2 and p38 MAP kinases were induced
by EGCG. Inhibition of cRaf-1 or ERK enhanced
EGCG-induced apoptosis, whereas inhibition of JNK or
p38 MAP kinase inhibited EGCG-induced apoptosis.
EGCG inhibited the activation of p90 ribosomal protein
S6 kinase, and induced the activation of cJUN
[77,78,84]. Xenograft and TRAMP models have shown
that green tea or EGCG can decrease the tumorigenic
potential of prostate cancer (7-10). These studies
demonstrate that EGCG induces growth arrest and
apoptosis through multiple mechanisms. Overall, these
findings suggest that green tea and its constituents can
be used for chemoprevention to target cancer stem cells.
The objectives of our study were to characterize pros-
tate cancer stem cells, and examine the molecular
mechanisms by which quercetin enhances the inhibitory
effects of EGCG on self-renewal capacity of prostate
cancer stem cells.
Results
CD44+ and CD133+ CSCs can be isolated from PC-3 and
LNCaP cells
The existence of stem-like cells in culture and xeno-
grafted tumors has been demonstrated [85-87]. There-
fore, we first examined the existence of CD44+ and
CD133+ CSCs in prostate cancer cell lines by flow cyto-
metry (Fig 1). Our data demonstrated the existence of
3.2% and 0.5% CD44+ plus CD133+ CSCs in both PC-3
and LNCaP cells, respectively. These results indicate the
possible presence of stem-like cells in PC-3 and LNCaP
cells.
EGCG inhibits the growth of cancer stem cells isolated
from human prostate cancer cell lines
Since CSCs has been successfully isolated from estab-
lished human cancer cells lines, we examined the
effects of EGCG on cancer stem cells (CD44+CD133+)
isolated from human prostate cancer cell lines (Fig. 2).
Isolated CSCs were grown in pancreatic cancer stem
cell medium in suspension and treated with various
doses SFN (0-10 μM) for 7 days. At the end of incuba-
tion period, spheroids were harvested, resuspended,
and cell viability was measured. EGCG inhibited viabi-
lity of prostate CSCs isolated from PC-3 and LNCaP
cell lines in a dose-dependent manner. These data sug-
gest that human prostate cancer cell lines possess a
Figure 1 The presence of CSCs in PC-3 and LNCaP cells. (A), PC-
3 cells were harvested, and stained with anti-CD44-FITC, anti-CD133-
PE or isotype control antibody. The presence of CD44+ and CD133+
cells were examined by the flowcytometry. (B), LNCaP cells were
harvested, and stained with anti-CD44-FITC, anti-CD133-PE or
isotype control antibody. The presence of CD44+ and CD133+ cells
were examined by the flowcytometry.
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small population of CSCs which are responsive to
EGCG treatment.
EGCG inhibits the formation of primary and secondary
tumor spheroids and cell viability of human prostate
cancer stem cells
Since EGCG inhibited the growth of CSCs isolated from
established prostate cancer cell lines, we sought to
examine whether EGCG could also inhibit the growth of
CSCs isolated from human primary prostate tumors. We
first examined the effects of EGCG on the CSC growth
by measuring spheroid formation and cell viability in
prostate CSCs expressing CD44+a2b1+CD133+. CSCs
were grown in prostate cancer stem cell defined med-
ium in suspension, and treated with EGCG for 7 days.
At the end of incubation period, spheroids in each well
were photographed. EGCG inhibited the growth of
spheroids in suspension in a dose-dependent manner
(Fig. 3A). The spheroids from each treatment group
were collected and resuspended for counting cell viabi-
lity. EGCG inhibited prostate CSC viability in a dose-
dependent manner (Fig. 3B).
Since EGCG inhibited the growth of tumor spheroid
and cell viability of CSCs, we next sought to examine
the effects of EGCG on colony formation. Prostate CSCs
were grown in agar, and treated with various doses of
EGCG for 3 weeks. At the end of incubation period,
colonies were counted. EGCG inhibited the growth of
colonies in a dose-dependent manner (Fig. 3C). These
data suggest that EGCG can be effective in inhibiting
the self-renewal capacity of prostate cancer stem cells.
Since CSCs appear to play a significant role in early
metastasis [13,41,88,89], we sought to measure the
effects of EGCG on invasion and migration of CSCs.
EGCG inhibited cell migration and invasion (Fig. 3D
and 3E). These data suggest that EGCG can be a useful
agent in targeting prostate cancer stem cells.
Inhibition of Nanog enhances the effects of EGCG on
spheroid formation by human prostate cancer stem cells
A high level of Nanog is a key regulator of embryonic
stem cell (ESC) self-renewal and puripotency [90,91].
Nanog-deficient ES cells and embryos lose their pluripo-
tency [92]. Since pluripotent transcription factor Nanog
is highly expressed in CSCs compared to normal cells
[93-97], we examined the effects of inhibiting Nanog on
antiproliferative effects of EGCG in human prostate
CSCs expressing (CD44+a2b1+CD133+). Lentiviral
mediated transduction of Nanog shRNA inhibited
Nanog protein expression (Fig. 4). EGCG inhibited stem
cell viability in CSC spheroids transduced with Nanog-
scrambled shRNA in a dose-dependent manner. The
inhibition of Nanog by shRNA further enhanced the
antiproliferative effects of EGCG on prostate CSCs.
These data suggest that inhibition of Nanog may be an
attractive target to enhance the anticancer activities of
EGCG in CSCs.
EGCG inhibits the expression of XIAP and Bcl-2 and
induces caspase-3 activation in human prostate cancer
stem cells
Since members of the IAP and Bcl-2 play important
roles in cell survival and apoptosis [98,99], we sought to
examine the effects of EGCG on the expression of
XIAP, Bcl-2 and survivin, activation of caspase-3/7 and
induction of apoptosis in prostate CSCs (Fig. 5). EGCG
inhibited the expression of XIAP, Bcl-2 and survivin in
prostate CSCs (Fig. 5A). Furthermore, EGCG induced
the activation of caspase-3/7 and apoptosis in prostate
Figure 2 Effects of EGCG on spheroid cell viability in cancer
stem cells (CSCs) derived from human prostate cancer cell
lines. (A), The CSCs were enriched from PC-3 cells, and grown in
suspension in keratinocyte serum-free medium supplemented with
B27, 10 ng/ml EGF, and 10 ng/ml basic fibroblast growth factor
(Invitrogen). Prostate CSCs were re-seeded in suspension and
treated with EGCG (0-60 μM) for 7 days. The spheroids were
dissociated with Accutase (Innovative Cell Technologies, Inc.), and
sieved through a 40-μm filter. Cell viability was measured by trypan
blue assay. For secondary sphere formation, CSCs were reseeded
and treated with EGCG for 7 days. Data represent mean ± SD. *, #,
% or ## = significantly different from control, P < 0.05. (B), Prostate
cancer stem cells were isolated from LNCaP cells, seeded in
suspension and treated with EGCG (0-60 μM) for 7 days. At the end
of incubation period, sheroids were dissociated with Accutase
(Innovative Cell Technologies, Inc.), and sieved through a 40-μm
filter. Cell viability was measured by trypan blue assay. Data
represent mean ± SD. *, #, % or ## = significantly different from
control, P < 0.05.
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CSCs in a dose-dependent manner (Fig. 5B and 5C).
These data suggest that EGCG can induce apoptosis in
CSCs by engaging cell-intrinsic pathway of apoptosis.
EGCG inhibits the expression of epithelial-mesenchymal
transition marker (EMT) in human prostate cancer stem
cells
During cancer metastasis, the mobility and invasiveness
of cancer cells increase. To detach from neighboring
cells and invade adjacent cell layers, carcinoma cells
must lose cell-cell adhesion and acquire motility. The
highly conserved EMT program has been implicated in
dissemination of carcinoma cells from primary epithelial
tumors [100]. Tumor progression is frequently asso-
ciated with the downregulation of E-cadherin [100], and
upregulation of vimentin and several transcription fac-
tors including Snail, Twist and Slug [101-103]. Cancer
stem cells undergoing metastasis usually express EMT
markers. We therefore examined the regulation of EMT
markers by EGCG. As expected, EGCG inhibited the
expression of vimentin, slug and snail (Fig. 6A). EGCG
also inhibited the expression of nuclear b-catenin in
Figure 3 Effects of EGCG on tumor spheroids and cell viability of prostate cancer stem cells (CSCs). (A), Prostate CSCs were seeded in
suspension and treated with EGCG (0-60 μM) for 7 days. Pictures of spheroids formed in suspension were taken by a microscope. (B), Prostate
CSCs were seeded in suspension and treated with EGCG (0-60 μM) for 7 days. At the end of incubation period, all the spheroids were collected
and resuspended. Cell viability was measured by trypan blue assay. Data represent mean ± SD. *, #, % or ## = significantly different from control,
P < 0.05. (c), EGCG inhibits colony formation by prostate CSCs. Prostate CSCs were seeded in soft agar and treated with various doses of EGCG
and incubated at 4°C for 21 days. At the end of incubation period, colonies were counted. Data represent mean ± SD. * or # = significantly
different from respective controls, P < 0.05. (D), Transwell migration assay. Prostate CSCs were plated in the top chamber of the transwell and
treated with EGCG (0-60 μM) for 24 h. Cells migrated to the lower chambered were fixed with methanol, stained with crystal violet and counted.
Data represent mean ± SD. * or # = significantly different from respective controls, P < 0.05. (E) Matrigel invasion assay. Prostate CSCs were
plated onto the Matrigel-coated membrane in the top chamber of the transwell and treated with EGCG (0-60 μM) for 48 h. Cells invaded to the
lower chambered were fixed with methanol, stained with crystal violet and counted. Data represent mean ± SD. * or # = significantly different
from respective controls, P < 0.05.
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prostate CSCs (Fig. 6B). We next examined the effects
of EGCG on TCF-1/LEF activity by reporter assay. As
shown in Fig. 6C, EGCG inhibited TCF-1/LEF activity
in prostate CSCs. These data suggest that inhibition of
EMT markers by EGCG could inhibit early metastasis of
cancer stem cells.
Quercetin enhances the effects of EGCG on cell viability
in spheroids, colony formation, apoptosis, migration and
invasion by prostate cancer stem cells
Quercetin has been shown to enhance the effects of
anticancer drugs and sensitize cancer cells to che-
motherapy [65,67,70,104-106]. We therefore examined
whether quercetin enhances the inhibitory effects of
EGCG on self-renewal, migration and invasion capaci-
ties of prostate CSCs (Fig. 7). EGCG inhibited cell via-
bility in spheroids, colony formation, migration and
invasion by CSCs in a dose-dependent manner (Fig.
7A,B,D and 7E). Quercetin, although effective alone,
further enhanced the biological effects of EGCG on
cell viability, colony formation, migration and invasion.
Furthermore, EGCG and quercetin alone induced
apoptosis (Fig. 7C). Interestingly, quercetin synergizes
with EGCG to induce apoptosis in prostate CSCs.
These data suggest that quercetin can be used with
EGCG to selectively target prostate CSCs.
Discussion
Our study demonstrates, for the first time, that cancer
preventive effects of EGCG and quercetin can inhibit
the self-renewal capacity of prostate cancer stem cells.
Our data are agreement with others who have demon-
strated that prostate cancer cell lines contain a small
population of cells having stem cell characteristics.
EGCG can synergies with quercetin to inhibit the self-
renewal capacity of prostate CSCs expressing CD44
+a2b1+CD133+. EGCG induces apoptosis by activating
capase-3/7, inhibiting Bcl-2, survivin and XIAP. EGCG
inhibits the expression of vimentin, slug, snail and
nuclear b-catenin which were accompanied by the inhi-
bition of TCF-1/LEF reporter activity. The inhibition of
EMT-related genes by EGCG suggests the blockade of
signaling involved in early metastasis. Interestingly,
quercetin synergizes with EGCG in inhibiting self-
renewal capacity of prostate CSCs and their migration
and invasion. These data suggest that EGCG either
alone or in combination with quercetin can eliminate
cancer stem cell-characteristics. Since carcinogenesis is a
complex process, combination of bioactive dietary
agents with complementary activities will be beneficial
for prostate cancer prevention and/or treatment.
Most carcinomas comprise of a heterogeneous cell
population with marked differences in their ability to
proliferate and differentiate as well as their ability to
reconstitute the tumor upon transplantation. Recent stu-
dies indicate the presence of a small, stem-like cell
population in several human cancers that is crucial for
the tumor repopulation. In a recent study, it has been
demonstrate that five out of six prostate cancer cell
lines formed clear holo-, mero-, and paraclones [87].
DU145 holoclones were maintained in culture for sev-
eral passages, which is indicative of self-renewal ability.
A small fraction (0.01%) of CD133+ cells was detected
in DU145 cell lines [87]. CD133+ cells; however, like
DU145 BCRP+ (0.15%) cells, they were not more clono-
genic, and they did not show more holoclone formation
than the marker-negative cells or unselected cells.
Immunohistochemistry revealed alpha2-integrin and
BCRP as potential stem cell markers and CK5 with the
combination of CK18 to distinguish transient amplifying
cells [87]. Similarly, in the present study, the propor-
tions of CD133+ cells in PC-3 and LNCaP cell lines
were 3.8% and 0.9%, respectively; and these cells were
able to form primary and secondary spheres. This led to
the hypothesis that the entire population of tumor cells
Figure 4 Inhibition of Nanog enhances the effects of EGCG on
CSC spheroid formation. CD133+ and CD44+ CSCs were isolated
from PC-3 cells and plated in six-well ultralow attached plates at a
density of 1,000 cells/ml. (A), CSCs were transduced with either
scrambled shRNA or Nanog shRNA expressing lentiviral vector
(pLKO.1), and cell lysates were collected and western blot analysis
was performed using anti-Nanog antibody. (B), CSC/scrambled and
CSC/Nanog shRNA were seeded as described above and treated
with EGCG (0-80 μM). After 7 days, spheroids were collected and
cell suspentions were prepared and viable cells were counted by
trypan blue assay. Data represent mean ± SD. * or ** = significantly
different from control, P < 0.05.
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might arise from a rare subpopulation of putative cancer
stem/progenitor-like cells, also known as tumor-initiat-
ing cells or cancer stem cells [20,87,107,108]. CSCs
share principle characteristics with adult stem cells
namely self-renewal, high proliferative potential, clono-
genicity, and multipotency. In addition, they have the
ability to reproducibly form the same tumor phenotype
as in the patient and to undergo differentiation into
non-tumorigenic cells [87,109,110]. TICs were first iso-
lated from patients with hematologic malignancies in
which a few cells could initiate a new tumor [111]. Dur-
ing the past few years, CSCs were also identified and
isolated from solid tumors such as breast, brain, colon,
pancreatic, and prostate tumors [14,15,112-117]. The
cancer stem cell hypothesis has provided a paradigm
shift in our understanding of carcinogenesis, metastasis,
and tumor biology. The identification of CSCs has
important implications in the way cancer treatment
should be conceived and future therapeutic approaches
will be designed. Whether the subpopulation of CSCs is
involved in the formation of distant metastases, tumor
dormancy and therapy resistance has remained poorly
understood.
The molecular mechanism by which CSCs (and the
supportive stroma) play roles in the formation of distant
metastases has remained largely elusive. The develop-
ment of more effective cancer therapies in advanced
prostate cancer may, thus, benefit from the outcome of
new studies and require selective targeting of this speci-
fic subpopulation of metastasis-initiating cells. In pros-
tate cancer, innovative studies have led to the
identification of CD44+/a2b1high/CD133+ prostate can-
cer stem cells [20,118]. Because of the observed hetero-
geneity in prostate cancer, the use of single-cell markers
for the selection, characterization/identification, and
functional evaluation of stem/progenitor-like prostate
cancer cells has been a major impediment and the relia-
bility of cell surface markers such as CD133 as the sole
way to isolate TICs remains controversial to date
[108,119]. Deregulation of ALDH enzyme activity is
implicated in the pathophysiology of various hematolo-
gic and epithelial cancers [120]. The introduction of
FACS-based viable cell sorting for ALDH activity
(ALDEFLUOR assays) in tumor biology has further sub-
stantiated a role of ALDHhi subpopulations of cancer
cells in carcinogenesis [114,121-123]. High ALDH
Figure 5 Regulation of apoptosis-related proteins, caspase-3/7 activity and apoptosis by EGCG on CSCs derived from human primary
prostate tumors. (A), Regulation of apoptosis-related proteins. Prostate CSCs from primary tumors were treated with EGCG (0-60 μM) for 48 h.
The Western blot analyses were performed to examine the expression of XIAP, Bcl-2 and survivin, and GAPDH. (B), Regulation of caspase-3/7
activity by EGCG. Prostate CSCs were treated with EGCG (0-60 μM) for 24 h, and caspase-3/7 activity was measured as per manufacturer’s
instructions. Data represent mean ± SD. * or ** = significantly different from control, P < 0.05. (C), Regulation of apoptosis by EGCG. Prostate
CSCs were treated with EGCG (0-60 μM) for 48 h, and apoptosis was measured by TUNEL assay. Data represent mean ± SD. * or ** =
significantly different from control, P < 0.05.
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activity, as detected by the ALDEFLUOR assay, can thus
be used as a functional marker to isolate TICs in several
types of epithelial cancers, including those of breast,
lung and colon [114,121-125]. A recent study has
demonstrated that high ALDH activity can be used to
isolate human prostate cancer cells with significantly
enhanced clonogenic and migratory properties in vitro
as well as elevated tumor- and metastasis-initiating abil-
ities in vivo [126]. The percentage of ALDHhi cells in
prostate cancer cell lines also seems to be related to
tumorigenicity and metastatic behavior.
Quercetin is a ubiquitous bioactive plant flavonoid
that has been shown to inhibit cell proliferation in sev-
eral cancer types. Quercetin has been shown to decrease
Akt phosphorylation and survivin expression in prostate
cancer cells [64,127]. Studies investigating molecular
mechanisms that underlie the inhibition of cell prolifera-
tion by quercetin demonstrated that a treatment includ-
ing quercetin triggered numerous cellular events
including DR5 upregulation [106,128-130], p53 activa-
tion [131-134], cell cycle arrest [58,59], and induction of
caspase-mediated apoptosis in cancer cells. Quercetin
down-regulates the expression of Hsp90 which, in turn,
induces growth inhibition and apoptosis in prostate can-
cer cells while exerting no quantifiable effect on normal
prostate epithelial cells. Quercetin has also been shown
to inhibit the expression of BCRP and MDR expression
[66,135,136]. In our study, quercetin has been able to
synergies with EGCG in inhibiting the self-renewal capa-
city of prostate CSCs, migration and invasion, and indu-
cing apoptosis. Since quercetin is a MDR modulator, it
can sensitize CSCs to anticancer drugs.
Recent evidence suggests a shared genomic fingerprint
between embryonic stem cells, cancer cells, and cancer
stem cells. Activation targets of Nanog, Oct4, Sox2 and
c-Myc are more frequently overexpressed in certain
tumors. In the absence of bona fide cancer stem cell
lines, human embryonic stem cells, which have similar
properties to cancer and cancer stem cells, have been an
excellent model throwing light on the anticancer affects
of various putative anticancer agents. Nanog, Sox2 and
Oct4 are transcription factors which are essential to
maintaining the pluripotent embryonic stem cell pheno-
type. Oct4 and Sox2 bind to the Nanog promoter in liv-
ing mouse and human ESCs [137]. Nanog, Oct4 and
Sox2 co-occupy and regulate their own promoters
together with other developmental genes with diverse
functions and collaborate to form an extensive regula-
tory circuitry including autoregulatory and feed-forward
loops [137-139]. A high level of Nanog is a key regulator
of ESC self-renewal and puripotency. Nanog-deficient
ES cells and embryos lose their pluripotency [92].
Nanog overexpression leads to the clonal expansion of
ES cells through circumvention of the LIF-dependent
Stat-3 pathway and sustained Oct-4 expression levels
[92,140]. Genome-wide gene expression profiling shows
that Nanog is expressed at high levels in testicular carci-
noma in situ and germ cell tumors [141]. Positive corre-
lations of Oct4, Nanog, or CD133 expression on tumor
stage were shown on oral squamous cell carcinoma
patient tissues [142]. In our study, inhibition of Nanog
Figure 6 Regulation of epithelial mesenchymal transition
factors by EGCG in prostate cancer stem cells isolated from
primary tumors. (A), Prostate CSCs were treated with EGCG (0-60
μM) for 48 h. At the end of incubation period, the expression of
vimentin, slug, and snail was measured by the Western blot analysis.
(B), Effects of EGCG on the expression of nuclear b-catenin. Prostate
CSCs were treated with EGCG (0-60 μM) for 48 h. At the end of
incubation period, cells were harvested and nuclear fractions were
prepared. The expression of b-catenin and GAPDH was measured
by was measured by the Western blot analysis. (c), Effects of EGCG
on TCF-1/LEF activity. Prostate CSCs were transduced with lentiviral
Top-dGFP-reporter (pRLR.sm-18.ppt). Transduced CSCs were treated
with EGCG (0-60) for 3 days and the GFP fluorescence was
measured. Data represent mean ± SD. * or ** = significantly
different from control, P < 0.05.
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by shRNA enhanced the inhibitory effects of EGCG on
tumor sphere formation and cell viability, suggesting its
requirement for self-renewal of CSCs. Medulloblastoma-
associated CSCs selected by serum-free medium with
bFGF and EGF can form 3 D spheroids and display
enhanced self-renewal and highly co-expressed stem cell
genes (Oct4, Nanog, Nestin, and Musashi-1) as well as
anti-apoptotic genes (Bcl-2 and Bcl-XL) [143]. These
finding suggest that inhibition of Nanog and/or other
pluripotent factors could be a novel strategy to kill
CSCs.
EMT is an embryonic program in which epithelial
cells lose their characteristics and gain mesenchymal
features. Therefore, EMT might play a very important
role during malignant tumor progression. Accumulating
evidence suggest that transformed epithelial cells can
activate embryonic programs of epithelial plasticity and
switch from a sessile, epithelial phenotype to a motile,
Figure 7 Quercetin synergizes with EGCG to inhibit self-renewal capacity of prostate cancer CSCs isolated from primary tumors. (A),
Quercetin synergizes with EGCG to inhibit spheroid cell viability. Prostate CSCs were seeded in suspension and treated with EGCG (0-60 μM)
with or without quercetin (20 μM) for 7 days. At the end of incubation period, all the spheroids were collected and resuspended. Cell viability
was measured by trypan blue assay. Data represent mean ± SD. *, &, **, @ or # = significantly different from control, P < 0.05. (B), Quercetin
synergizes with EGCG to inhibit colony formation. Prostate CSCs were seeded in soft agar and treated with various doses of EGCG (0-60 μM)
with or without quercetin (20 μM) and incubated at 4°C for 21 days. At the end of incubation period, colonies were counted. Data represent
mean ± SD. *, &, **, @ or # = significantly different from control, P < 0.05. (C), Quercetin synergizes with EGCG to induce apoptosis. Prostate
CSCs were seeded in suspension and treated with EGCG (0-60 μM) with or without quercetin (20 μM) for 7 days. At the end of incubation
period, all the spheroids were collected. Apoptosis was measured by TUNEL assay. Data represent mean ± SD. *, &, **, @ or # = significantly
different from control, P < 0.05. (D), Migration assay. Prostate CSCs were plated in the top chamber of the transwell and treated with EGCG (0-60
μM) with or without quercetin (20 μM) for 24 h. Cells migrated to the lower chambered were fixed with methanol, stained with crystal violet
and counted. Data represent mean ± SD. *, &, **, @ or # = significantly different from control, P < 0.05. (E) Matrigel invasion assay. Prostate CSCs
were plated onto the Matrigel-coated membrane in the top chamber of the transwell and treated with EGCG (0-60 μM) with or without
quercetin (20 μM) for 48 h. Cells invaded to the lower chambered were fixed with methanol, stained with crystal violet and counted. Data
represent mean ± SD. *, &, **, @ or # = significantly different from control, P < 0.05.
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mesenchymal phenotype. Induction of EMT can, there-
fore, lead to invasion of surrounding stroma, intravasa-
tion, dissemination and colonization of distant sites.
Under the cancer stem cell hypothesis, sustained meta-
static growth requires the dissemination of a CSC from
the primary tumor followed by its re-establishment in a
secondary site. In the present study, EGCG inhibited the
expression of EMT markers (expression of vimentin,
nuclear b-catenin and TCF-1/LEF reporter activity) and
also inhibited the transcription factors slug and snail,
which are required for induction of EMT. The inhibition
of EMT markers by EGCG suggests that it could inhibit
early metastasis of prostate CSCs. Furthermore, querce-
tin will further enhance the biological effects of EGCG
in inhibiting EMT and hence early metastasis.
In conclusion, we have demonstrated that EGCG
inhibited self-renewal capacity of prostate CSCs, and
these properties of EGCG were further enhanced by
quercetin. EGCG inhibited the expression of transcrip-
tion factors which are required for maintaining stem-
cell pluripotency. Inhibition of Nanog could be consid-
ered as a novel strategy to enhance the biological effects
of anticancer and chemopreventive agents or sensitize
those cells which are resistant to chemotherapy or irra-
diation. Moreover, EGCG inhibited expression of pro-
teins involved in the EMT, suggesting the blockade of
signaling involved in early metastasis. Furthermore,
combination of quercetin with EGCG had synergistic
inhibitory effects on self-renewal and metastatic proper-
ties of prostate CSCs. These data suggest that EGCG
either alone or in combination with quercetin can be
used for the prevention and/or treatment of prostate
cancer. However, further studies are needed to validate
the combination of EGCG and quercetin in an appropri-
ate in vivo model.
Methods
Reagents
Antibodies against b-catenine, vimentin, slug, snail,
GAPDH, XIAP, survivin, Bcl-2, and Nanog were pur-
chased from Cell Signaling Technology, Inc. (Danvers,
MA). EGCG and quercetin were purchased from LKT
Laboratories, Inc. (St. Paul, MN). Enhanced chemilumi-
nescence (ECL) Western blot detection reagents were
from Amersham Life Sciences Inc. (Arlington Heights,
IL). Terminal Deoxynucleotidyl Transferase Biotin-
dUTP Nick End Labeling (TUNEL) assay kit was pur-
chased from EMD Biosciences/Calbiochem (San Diego,
CA). All other chemicals were purchased from Sigma-
Aldrich (St Luis, MO).
Cell Culture
PC-3 and LNCaP cells were obtained from the Ameri-
can Type Culture Collection (Manassas, VA). Human
prostate cancer stem cells (CD44+a2b1+CD133+) were
from Celprogen Inc. (San Pedro, CA). CSCs were cul-
tured in DMEM supplemented with 1% N2 Supplement
(Invitrogen), 2% B27 Supplement (Invitrogen), 20 ng/ml
human platelet growth factor (Sigma-Aldrich), 100 ng/
ml epidermal growth factor (Invitrogen) and 1% antibio-
tic-antimycotic (Invitrogen) at 37°C in a humidified
atmosphere of 95% air and 5% CO2.
Tumor Spheroid Assay
Spheroid forming assays were performed as described
elsewhere [144,145]. In brief, single cells were plated in
six-well ultralow attachment plates (Corning Inc., Corn-
ing, NY) at a density of 1,000 cells/ml in DMEM supple-
mented with 1% N2 Supplement (Invitrogen), 2% B27
Supplement (Invitrogen), 20 ng/ml human platelet
growth factor (Sigma-Aldrich), 100 ng/ml epidermal
growth factor (Invitrogen) and 1% antibiotic-antimycotic
(Invitrogen) at 37°C in a humidified atmosphere of 95%
air and 5% CO2. Spheroid were collected after 7 days
and dissociated with Accutase (Innovative Cell Technol-
ogies, Inc.). The cells obtained from dissociation were
sieved through a 40-μm filter, and counted by coulter
counter using trypan blue dye.
Soft agar colony assay
Cell suspensions (2,500 cells) were prepared using 0.4%
Noble agarose (Becton Dickinson) and overlayed onto a
60-mm dish containing a solidified bottom layer of 0.6%
agarose in medium. Once the top layer solidified, 1 ml
of medium was placed on top of the cell layer. After
treatment, plates were incubated for 3 weeks and colo-
nies were counted by using microscopy.
Transwell Migration assay
For transwell migration assays, 1 × 105 prostate CSCs
were plated in the top chamber onto the noncoated
membrane (24-well insert; pore size, 8 μm; Corning
Costar) and allowed to migrate toward serum-containing
medium in the lower chamber. Cells were fixed after
24 hours of incubation with methanol and stained with
0.1% crystal violet (2 mg/mL, Sigma-Aldrich). The num-
ber of cells invading through the membrane was
counted under a light microscope (40×, three random
fields per well).
Transwell invasion assay
For invasion assay, 1 × 105 cells were plated in the top
chamber onto the Matrigel coated Membrane (24-well
insert; pore size, 8 μm; Corning Costar). Each well was
coated freshly with Matrigel (60 μg; BD Bioscience)
before the invasion assay. Cells were plated in medium
without serum or growth factors, and medium supple-
mented with serum was used as a chemoattractant in
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the lower chamber. The cells were incubated for
48 hours and cells that did invade through the pores
were removed by a cotton swab. Cells on the lower sur-
face of the membrane were fixed with methanol and
stained with crystal violet. The number of cells invading
through the membrane was counted under a light
microscope (40×, three random fields per well).
Viral production and infection
Nanog shRNA construct (pLKO.1-puro, Mission RNAi)
was from Open Biosystems. Lentiviral-TOP-dGFP-
reporter (pRRL.sin-18.ppt) has been described elsewhere
[146]. Lentivirus was produced by triple transfection of
HEK 293T cells. Viral supernatants were collected and
concentrated by ultracentrifugation to produce virus
stocks with titers of 1 × 108 to 1 × 109 infectious units
per milliliter. Viral supernatant was collected for three
days by ultracentrifugation and concentrated 100-fold
[147]. Titers were determined on HEK293T cells.
Human prostate CSCs were transduced with a mixture
of viral particles and polybrene with two rounds of
infections [147].
Lentiviral reporter assays
The enhanced d2-eGFP gene (Clontech) was cloned
downstream of a LEF-1/TCF-responsive promoter (b-
catenin reporter), containing three LEF-1/TCF binding
motifs and a TATA box [148]. This cassette was then
cloned into a self-inactivating lentiviral vector plasmid
(pRRL.sin-18.ppt), and virus was produced as described
above. For in vitro assays, transduced CSCs were plated
at 1,000 cells per well in 96-well plates and treated with
EGCG and/or quercetin. After incubation, CSCs were
analyzed for GFP expression.
Caspase-3/7 Assay
Cells (3 × 104 per well) were seeded in a 96-well plate
with 200 μl culture medium. Approximately 16 h later,
cells were treated with various doses of EGCG with or
without quercetin. Casapse-3/7 activity was measured by
a fluorometer as per manufacturer’s instructions
(Invitrogen).
Western Blot Analysis
Western blots were performed as we described earlier
[149,150]. In brief, cells were lysed in RIPA buffer con-
taining 1 × protease inhibitor cocktail, and protein con-
centrations were determined using the Bradford assay
(Bio-Rad, Philadelphia, PA). Proteins were separated by
12.5% SDS/PAGE and transferred to membranes (Milli-
pore, Bedford, MA) at 55 V for 4 h at 4°C. After block-
ing in 5% nonfat dry milk in TBS, the membranes were
incubated with primary antibodies at 1:1,000 dilution in
TBS overnight at 4°C, washed three times with
TBS-Tween 20, and then incubated with secondary anti-
bodies conjugated with horseradish peroxidase at
1:5,000 dilution in TBS for 1 hour at room temperature.
Membranes were washed again in TBS-Tween 20 for
three times at room temperature. Protein bands were
visualized on X-ray film using an enhanced chemilumi-
nescence detection system.
Statistical Analysis
The mean and SD were calculated for each experimental
group. Differences between groups were analyzed by one
or two way ANOVA, followed by Bonferoni’s multiple
comparison tests using PRISM statistical analysis soft-
ware (GrafPad Software, Inc., San Diego, CA). Signi-
ficant differences among groups were calculated at
P < 0.05.
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